Cheap, Generic 'Biologics' on the Way?
Congress Considers Allowing Companies to Make Low-Cost Copies of Drugs Like Insulin
Generic drugs can cost half of their identical brand-name "parents,"
and insurers, employers, and patients credit them with savings billions in
health costs each year. The copies are made by mimicking chemical active
ingredients in a laboratory.
But biologics contain active molecules far larger and more complex than
those in existing generics. Those molecules can't be precisely copied
synthetically, and brand-name drugmakers closely guard information about the
delicate and complicated biological reactions needed to produce them
Brand-name drugmakers maintain that the uncertainty makes generic biologics
inherently unreliable and potentially unsafe. They want Congress to bar
biologic generics from FDA rules that let drug companies make them without
putting them through expensive human clinical studies.
"[Generic] biologics can be shown to be similar, but never identical, to
an innovator," said Jay P. Siegel, MD, president of biotechnology,
immunology, and oncology research and development at Johnson & Johnson, one
of the world's largest manufacturers of biologics.
"You can't just take a molecule that has never been in people ... then
all of the sudden market it to thousands of people. It's too risky," he
Generic Companies: We Can Do It
Generic manufacturers, meanwhile, say technology now allows them to
backtrack from a biologic's ingredients and closely approximate its molecular
structure. They accuse brand-name companies of stonewalling for fear of losing
billions in revenues.
"The science is here and has been for over a decade," said Ajaz S.
Hussain, vice president for biopharmaceutical development at Sandoz, a generic
company owned by Novartis.
Complex as a 'Skyscraper'
A bill introduced last month would give the FDA the power for fast-track
approval of generic biologics on a case-by-case basis, as long as companies can
show they are essentially equivalent to the brand-name parent.
"The science supports an abbreviated pathway for [generic]
biologics," said Sen. Hillary Rodham Clinton, D-N.Y., one of several
sponsors of the bill. "We are finally at a place where we are debating how,
Meanwhile, several key Republicans said the bill does not do enough to
ensure the safety and effectiveness of highly complex biologic drugs.
Wyoming Sen. Mike Enzi, the senior Republican on the Senate Health,
Education, Labor, and Pensions Committee, said if traditional drugs are as
complex as a house, biologics were more akin to "a skyscraper."
"One girder out of place could cause the entire structure to fall,"